1 Title

Going beyond clinical routine in SARS-CoV-2 antibody testing - A multiplex corona virus
antibody test for the evaluation of cross-reactivity to endemic coronavirus antigens

4

5 Authors

Matthias Becker^{1,#}, Monika Strengert^{2,3,#}, Daniel Junker¹, Tobias Kerrinnes⁴, Philipp D. Kaiser¹, 6 Bjoern Traenkle^{1,16}, Heiko Dinter^{1,16}, Julia Häring¹, Anne Zeck¹, Frank Weise¹, Andreas 7 Peter^{5,21,22}, Sebastian Hörber^{5,21,22}, Simon Fink¹, Felix Ruoff¹, Tamam Bakchoul⁹, Armin 8 Baillot¹⁰, Stefan Lohse¹¹, Markus Cornberg¹², Thomas Illig¹³, Jens Gottlieb¹⁴, Sigrun Smola¹¹, 9 André Karch¹⁷, Klaus Berger¹⁷, Hans-Georg Rammensee^{6,7,8}, Katja Schenke-Layland^{1,8,18,19}, 10 Annika Nelde^{6,8,20}, Melanie Märklin^{8,20}, Jonas S. Heitmann^{8,20}, Juliane S. Walz^{6,8,15,20}, Markus 11 Templin¹, Thomas O. Joos¹, Ulrich Rothbauer^{1,16,#}, Gérard Krause^{2,3}, Nicole Schneiderhan-12 Marra^{1,*} 13

14

15 Affiliations

- ¹ NMI Natural and Medical Sciences Institute at the University of Tuebingen, Germany
- ² Department of Epidemiology, Helmholtz Centre for Infection Research, Braunschweig,
- 18 Germany

³ TWINCORE GmbH, Centre for Experimental and Clinical Infection Research, a joint venture

20 of the Hannover Medical School and the Helmholtz Centre for Infection Research, Hannover,

21 Germany

- ⁴ Helmholtz-Institute for RNA-based Infection Research (HIRI), Würzburg, Germany
- ⁵ Institute for Clinical Chemistry and Pathobiochemistry, Department for Diagnostic Laboratory
- 24 Medicine, University Hospital Tuebingen, Tuebingen, Germany
- ⁶ Institute for Cell Biology, Department of Immunology, University of Tuebingen, Tuebingen,
 Germany
- ⁷ German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), partner
- NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. Site Tuebingen, Tuebingen, Germany.

- ⁸ Cluster of Excellence iFIT (EXC2180) "Image-Guided and Functionally Instructed Tumor
- 30 Therapies", University of Tuebingen, Tuebingen, Germany
- ⁹ Institute for Clinical and Experimental Transfusion Medicine, University Hospital Tuebingen,
- 32 Tuebingen, Germany
- ¹⁰ Niedersächsisches Landesgesundheitsamt, Department of Virology/Serology, Hannover,
- 34 Germany
- ¹¹ Institute of Virology, Saarland University Medical Center, Homburg/Saar, Germany
- ¹² Department of Gastroenterology, Hepatology, Endocrinology, Hannover Medical School,
- 37 Hannover, Germany; Centre for Individualized Infection Medicine (CiiM), Hannover, Germany
- ¹³ Hannover Unified Biobank (HUB), Hannover Medical School, Hannover, Germany
- ¹⁴ Clinic for Pneumonology, Hannover Medical School, Hannover, Germany
- ¹⁵ Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University
- 41 Hospital Tuebingen, Tuebingen, Germany
- ¹⁶ Pharmaceutical Biotechnology, University of Tuebingen, Germany
- 43 ¹⁷ Institute of Epidemiology and Social Medicine, University of Münster, Münster, Germany
- ¹⁸ Department of Women's Health, Research Institute for Womens's Health, Eberhard-Karls-
- 45 University, Tuebingen, Germany
- ¹⁹ Department of Medicine/Cardiology, Cardiovascular Research Laboratories, David Geffen
- 47 School of Medicine at UCLA, Los Angeles, CA, USA
- 48 ²⁰ Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK),
- 49 Department of Internal Medicine, University Hospital Tuebingen, Tuebingen, Germany
- ²¹ Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich at
- 51 the University of Tuebingen, Tuebingen, Germany
- 52 ²² German Center for Diabetes Research (DZD), München-Neuherberg, Germany
- [#] These authors contributed equally to this work.
- 54
- 55
- 56

- 57 * Corresponding author:
- 58 Dr. Nicole Schneiderhan-Marra
- 59 Markwiesenstrasse 55, 72770 Reutlingen, Germany
- 60 Phone: 0049 7121 51530 815
- 61 Fax: 0049 7121 51530 16
- 62 E-Mail: Nicole.Schneiderhan@nmi.de

63 Abstract

Given the importance of the humoral immune response to SARS-CoV-2 as a global benchmark 64 65 for immunity, a detailed analysis is needed to monitor seroconversion in the general population, 66 understand manifestation and progression of COVID-19 disease, and ultimately predict the outcome of vaccine development. In contrast to currently available serological assays, which 67 are only able to resolve the SARS-CoV-2 antibody response on an individual antigen level, we 68 developed a multiplex immunoassay, for which we included spike and nucleocapsid proteins 69 70 of SARS-CoV-2 and the endemic human coronaviruses (NL63, OC43, 229E, HKU1) in an 71 expanded antigen panel. Compared to three commercial in vitro diagnostic tests, our MULTICOV-AB assay achieved the highest sensitivity and specificity when analyzing a well-72 characterized sample set of SARS-CoV-2 infected and uninfected individuals. Simultaneously, 73 high IgG responses against endemic coronaviruses became apparent throughout all samples. 74 75 but no consistent cross-reactive IgG response patterns could be defined. In summary, we have established and validated, a robust, high-content-enabled, and antigen-saving multiplex assay 76 MULTICOV-AB, which is highly suited to monitor vaccination studies and will facilitate 77 epidemiologic screenings for the humoral immunity toward pandemic as well as endemic 78 79 coronaviruses.

81 Introduction

Given the importance of the humoral immune response to SARS-CoV-2 as a global benchmark 82 83 for immunity, a detailed analysis is needed to (i) monitor seroconversion in the general population^{1,2}, (ii) understand manifestation and progression of the disease^{3,4}, and (iii) predict 84 the outcome of vaccine development^{5,6}. Currently available serological assays utilize single 85 analyte technologies such as ELISA to measure antibodies against SARS-CoV-2 antigens 86 87 including spike (S) or nucleocapsid (N) protein^{1,6-8}. To measure individual antibody (IgG and IgA) responses against SARS-CoV-2 and the endemic human coronaviruses (hCoVs) NL63, 88 89 229E, OC43, and HKU1, we developed a multiplexed immunoassay (MultiCoV-Ab), for which we included S and N proteins of these coronaviruses in an expanded antigen panel. Compared 90 to commercial in vitro diagnostic (IVD) tests our MultiCoV-Ab assay achieved the highest 91 sensitivity and specificity when analyzing 310 SARS-CoV-2 infected and 866 uninfected 92 individuals. Simultaneously we see high IgG responses against hCoVs throughout all samples, 93 whereas no consistent cross reactive IgG response patterns can be defined. In summary, our 94 95 MultiCoV-Ab assay is highly suited to monitor vaccination studies and will facilitate 96 epidemiologic screenings for the humoral immunity toward pandemic as well as endemic 97 coronaviruses.

98 Results

To investigate the antibody response of SARS-CoV-2-infected individuals, we developed and 99 100 established a high-throughput and automatable bead-based multiplex assay, termed MultiCoV-Ab. We expressed and immobilized six different SARS-CoV-2-specific antigens on 101 Luminex MAGPLEX beads with distinct color codes, specifically the trimeric full-length Spike 102 protein (Spike Trimer), receptor binding domain (RBD), S1 domain (S1), S2 domain (S2), full-103 104 length nucleocapsid (N) and the N-terminal domain of nucleocapsid (N-NTD) (Extended Data 105 Fig. 1). Immunoglobulins from serum and plasma samples were detected using phycoerythrin-106 labelled anti-human IgG or IgA antibodies. Data on quality control and assay performance is provided in Extended Data Fig. 2 and Extended Data Table 1. 107

As key antigens for the classification of SARS-CoV-2-induced seroconversion, we used Spike 108 Trimer and RBD previously described by Amanat et. al², and initially screened a set of 205 109 SARS-CoV-2-infected and 72 uninfected individuals with the MultiCoV-Ab assay. Using a 110 combined cut-off of both antigens, we identified all uninfected samples as negative (Fig. 1a). 111 112 Of the 205 infected samples, the MultiCoV-Ab assay identified 24 (11.7%) as IgG antibodynegative. This finding is supported by three other commercially available IVD tests (Roche⁹. 113 Siemens Healthineers¹⁰, Euroimmun¹¹) widely used in clinical routine SARS-CoV-2 antibody 114 testing. However, the IVD tests missed additional 8 (Roche), 11 (Siemens Healthineers) and 115 116 9 (Euroimmun) samples of SARS-CoV-2-infected individuals. Furthermore, the Euroimmun test classified 8 additional samples as "borderline" (Fig. 1b, Extended Fig. 3a-c). In 117 accordance with our MultiCoV-Ab assay, no samples were classified as false positives by the 118 Roche and Siemens tests, whereas one sample was classified as false positive and one as 119 120 "borderline" by the Euroimmun test.

When testing for IgA antibodies in samples of SARS-CoV-2-infected individuals, our MultiCoVAb assay classified 47 (22.9 %) as IgA-negative, whereas the Euroimmun test classified 32
(15.6 %) as IgA-negative, and 16 (7.8 %) as borderline (Fig. 1b and Extended Data Fig. 3d).
For the uninfected samples, the Euroimmun test identified 7 (9.7 %) as false positives and 3

(4.2 %) as "borderline", whereas no samples were classified as false positives by the MultiCoV-Ab assay.

127 Next, we used an extended sample set with 310 SARS-CoV-2-infected and 866 uninfected donors for clinical validation of MultiCoV-Ab assay. A simplified overview of this set is shown 128 in Fig. 2a; a complete breakdown is displayed in Extended Data Table 2. A direct comparison 129 revealed that Spike Trimer and RBD were the best predictors of SARS-CoV-2 infection. Signal 130 cut-offs were defined for both, IgG and IgA detection, based on ROC analysis with focus on 131 132 maximum specificity. Additionally, we defined a cut-off for overall IgG and IgA positivity for which both individual cut-offs for Spike Trimer and RBD had to be met (Fig. 2b). As shown 133 above, cut-offs based on IgG were shown to be more sensitive and specific than those based 134 on IgA. With the IgG overall cut-off, we reached a specificity of 100 % (Fig. 2c), which would 135 136 not have been possible for either of the antigens individually, while still retaining acceptable sensitivity. To identify samples with an early immune response, we simultaneously measured 137 138 IgA response. With the MultiCoV-Ab assay, we identified eight IgA-positive samples that 139 showed no IgG response (Fig. 2d). Two of these were uninfected and falsely classified as 140 positive. For four of the remaining six infected samples, details regarding the time between the 141 onset of symptoms and sample drawing were available (2, 6, 7, and 15 days). We hypothesized that IqA in these samples can be used to measure an early onset of antibody response. Thus, 142 143 we classified samples with strong IgA positivity - signal to cut-off (S/CO) > 2 for Spike Trimer 144 and RBD - as "positive", irrespective of their detected IgG response. With this 145 combined IgG + IgA classification, we reached an optimal sensitivity of 90 % while retaining a specificity of 100 %. 146

Further analyzing the Ig response towards both subdomains of the spike, S1 and S2, we achieved no additional sensitivity for the classifier (**Fig. 2e**). Interestingly, RBD, as a part of S1, showed much fewer uninfected samples with increased IgG response compared to S1. For S2 even more uninfected samples had increased signals, pointing to potential crossreactivity in this domain of the spike protein (**Fig. 2e**). We further complemented our assay with the N and N-NTD proteins. Although these antigens were successfully used in single-

analyte assays¹², we observed a high cross reactivity in uninfected samples for both (Fig. 2f).
Across the entire data set, only one sample showed a distinct immune response to N and NNTD, but not to all spike derived antigens.

Longitudinal samples from five hospitalized patients were subjected to a small-scale time 156 course analysis of IgG and IgA immune responses (Fig. 3a). Levels of both Ig classes strongly 157 increased within the first ten days after the onset of symptoms. While IgG levels appeared 158 159 constant over roughly two months, IgA levels started to decline between day 10 and 20 after 160 the onset of symptoms where samples were available. These effects were consistent for the majority of SARS-CoV-2 antigens. Furthermore, we found that patients' hospitalization, as a 161 measure of disease severity (Fig. 3b), seemed to correlate with an increased humoral immune 162 response, especially in IgA. Furthermore, there is indication for a trend for increasing age as 163 well (Fig. 3c). However, it should be considered that patients of higher age also had a higher 164 rate of hospitalization in our study population. 165

166 In order to explore cross-reactivity of hCoVs with SARS-CoV-2, we included S1, N, and N-NTD 167 antigens from human α- (NL63 and 229E) and β-hCoVs (OC43 and HKU1) in our MultiCoV-168 Ab panel (Extended Data Fig. 1). The immune response towards all hCoV antigens was more 169 dependent on coronavirus clade than on N or S1 antigen. However, within the clades of α hCoVs and β -hCoVs, types of antigens were more dominant than the virus subtype, as 170 171 demonstrated by rank correlation analysis and hierarchical clustering. Interestingly, IgG 172 response against α -hCoVs clustered more closely to SARS-CoV-2 than to β -hCoVs (**Fig. 4a**, 173 **Extended Data Fig. 4a**). Overall, we identified a considerable immune response to hCoV antigens throughout the whole sample set with no notable differences between samples from 174 175 SARS-CoV-2-infected and uninfected donors in IgG or IgA for S1 (Fig. 4b), N (Fig. 4c), or N-

176 NTD (**Extended Data Fig. 4b**).

We therefore used the IgG signal relative to the average response per antigen for further analyses, which allowed comparison among all hCoV antigens on one scale. For those uninfected samples, which showed an IgG cross reactivity towards Spike Trimer (Spike Trimer false positives), we observed partially increased responses towards hCoV antigens. Those

181 samples, which did not show an immune response after SARS-CoV-2 infection (false 182 negatives, as determined by MultiCoV-Ab assay, combined IgG + IgA) were closer to the 183 baseline (**Fig. 4d-e, Extended Data Fig. 4c**). This indicates that cross-reactivity with hCoVs 184 causes some of the observed SARS-CoV-2 immune response in samples taken from 185 individuals not exposed to SARS-CoV-2.

To investigate the correlation of hCoV and SARS-CoV-2 immune response further, we grouped 186 187 samples into high and low responders for α -hCoVs and β -hCoVs. High responders had relative 188 IgG signals > 0 for N and S1 antigens of both hCoV subtypes within the clade, while lowresponders had < 0, respectively. Samples with SARS-CoV-2 immune response (as 189 190 determined by MultiCoV-Ab assay, combined IgG + IgA classification) were significantly overrepresented within the group of α -hCoV high responders (p = 3.78e-03, Fisher's exact 191 test, two sided), while being significantly underrepresented within the group of α -hCoV and β -192 hCoV low responders (p = 1.14e-03 and p = 1.56e-02, respectively, Fisher's exact test, two 193 194 sided) (Fig. 4f). These results showed that while there were no discernible global effects for 195 single antigens, there is a correlation between the SARS-CoV-2 immune response with high 196 hCoV responses, especially towards α -hCoVs.

197 Discussion

We demonstrated that our MultiCoV-Ab, a novel multiplex assay, is highly suitable to classify 198 199 seroconversion in SARS-CoV-2-infected individuals. With a combined cut-off using SARS-200 CoV-2 trimeric full-length spike protein and RBD, we were able to eliminate false positive responses and achieved a sensitivity of 90% with a specificity of 100% for 310 samples from 201 202 SARS-CoV-2-infected and for 866 samples from uninfected individuals. We found that 203 detection of IgG more accurately reflected infection compared to IgA, although both were highly 204 specific. However, by simultaneously monitoring IgA, we additionally were able to detect an 205 early immune response in some patients. The MultiCoV-Ab approach allows the easy addition of SARS-CoV-2-specific antigens, here six in total, which provides an additional level of 206 207 confidence in patient classification. Thus, for example, we noticed that the spike S1 domain showed fewer false positive responses compared to the S2 domain. Interestingly, Ng et al.¹³ 208 reported reactivity towards SARS-CoV-2 S2 from sera of patients with recent seasonal hCoV 209 infection. These sera prevented infection with SARS-CoV-2 pseudotypes in a neutralization 210 211 assay. Additionally, we found that spike non-responders also did not show a response to nucleocapsid, which has been described as strongest inducer of antibody responses^{12,14}; and 212 213 not vice versa.

In our comparison to commercially available IVD tests, we classified fewer samples as false negative using our MultiCoV-Ab assay. For 10% of all infected samples, we could not detect a SARS-CoV-2 specific immune response, which is in line with previous findings^{3,15,16}. Those non-responders may be able to limit viral replication by innate immune mechanisms or cellular immunity is dominant in mediating viral clearance^{17,18}.

Expanding our MultiCoV-Ab assay to the endemic hCoVs NL63, 229E, OC43, and HKU1 revealed a clear IgG immune response for all tested samples. Furthermore, we did not observe a difference for the samples from proven hCoV-infected individuals, compared to other samples. Due to the general lack of availability of samples from hCoV-naïve individuals, it was difficult to analyze hCoV-mediated cross-reactivity. Nevertheless, our multiplexed readout indicates a correlation between the SARS-CoV-2 immune response and high hCoV responses.

225 Currently, we are identifying population groups which were highly exposed and showed 226 different susceptibility to SARS-CoV-2 infection, e.g. the "Ischgl-study group" (unpublished 227 data)¹⁹, in order to elucidate potential cross protection derived from immune responses towards 228 endemic hCoVs in more detail. Alternatively, studies analyzing hCoV signatures in samples 229 from individuals before and after SARS-CoV-2 infection using the MultiCoV-Ab assay would 230 help to get insight into a potential cross protection.

A multiplex setup such as MultiCoV-Ab assay is especially suited to vaccination studies, since the flexibility and broad antigen coverage allows to efficiently map vaccine immune responses to an immunoglobulin isotype and subtype level for the target pathogen and related species ²⁰. Interestingly, previous SARS-CoV-1 vaccine studies clearly indicated that a detailed characterization of vaccine-induced antibody responses is mandatory for efficient coronavirus vaccine development^{21,22}.

In summary, we have established and validated the MultiCoV-Ab assay, a robust, highcontent-enabled, and antigen-saving multiplex assay. This assay is suitable for comprehensive characterization of SARS-CoV-2 infection on the humoral immune response and for epidemiological screenings to accurately measure SARS-CoV-2 seroprevalence in large cohort studies. It further provides the unique opportunity to assess and correlate immunity for both endemic and pathogenic coronaviruses. Finally, the multiplex nature of the MultiCoV-Ab assay can deliver urgently needed data on the outcome of SARS-CoV-2 vaccination.

244 Supplementary - Materials and Methods

245 Generation of expression constructs for production of viral antigens

246 The cDNAs encoding the full-length nucleocapsid proteins of SARS-CoV-2, hCoV-OC43, hCoV-NL63, hCoV-229E, and hCoV-HKU1 (GenBank accession numbers QHD43423.2; 247 YP 009555245.1; YP 003771.1; NP 073556.1; YP 173242.1) were produced with an N-248 terminal hexahistidine (His₆)-tag by DNA synthesis (ThermoFisher Scientific). The cDNAs were 249 250 cloned by standard techniques into Ndel/HindIII sites of the bacterial expression vector 251 pRSET2b (ThermoFisher Scientific). To generate N-terminal domains (NTDs) of the respective nucleocapsid proteins (SARS-CoV-2 NTD aa 1-189; hCoV-OC43 NTD aa 1-204; hCoV-NL63 252 NTD aa 1 - 154; hCoV-229E NTD aa 1-156; hCoV-HKU1 NTD aa 1- 203), a stop codon located 253 N-terminally to the Serine-Arginine (SR)-rich linker site²³ was introduced via PCR mutagenesis 254 of the nucleocapsid encoding plasmids using the forward primer pRSET2b down-for 5' - GGT 255 AAG CTT GAT CCG GCT GCT AA - 3' and respective reverse primers: SARS-CoV2 NTD-rev 256 5' - GGG AAG CTT ACT CAG CAT AGA AGC CCT TTG G - 3', OC43 NTD-rev 5' - GGG AAG 257 258 CTT ATT CGA TAT AAT AGC CCT GCG G - 3', NL63 NTD-rev 5' - GGG AAG CTT ATT CAA CAA CGC TCA GTT CCG - 3', 229E NTD-rev 5' - GGG AAG CTT ATT CAA CAA CGG TAA 259 CAC CAT TC - 3' and HKU1 NTD-rev 5' - GGG AAG CTT ATT CCA CAT AGT AGC CCT 260 GAG GC - 3'. 261

The pCAGGS plasmids encoding the stabilized trimeric Spike protein and the receptor binding
 domain (RBD) of SARS-CoV-2 were kindly provided by F. Krammer².

The cDNA encoding the S1 domain (aa 1 - 681) of the SARS-CoV-2 Spike protein was obtained by PCR amplification using the forward primer S1_CoV2-for 5′- CTT CTG GCG TGT GAC CGG - 3′ and reverse primer S1_CoV2-rev 5′ - GTT GCG GCC GCT TAG TGG TGG TGG TGG TGG GGG CTG TTT GTC TGT GTC TG - 3′ and the full length SARS-CoV-2 SPIKE cDNA as template and cloned into the Xbal/NotI-digested backbone of the pCAGGS vector, thereby adding a C-terminal His₀-Tag.

The cDNAs encoding the S1 domains of hCoV-OC43 (aa 1 -760), hCoV-NL63 (aa 1 - 744), hCoV-229E (aa 1 - 561) and hCoV-HKU1 (aa 1 - 755) (GenBank accession numbers

AVR40344.1; APF29071.1; YP_003771.1; APT69883.1; AGW27881.1) were produced by DNA synthesis (ThermoFisher Scientific), digested using Xbal/NotI and ligated into the pCAGGS vector. All expression constructs were verified by sequence analysis.

275

276 **Protein expression and purification**

For expression of the viral nucleocapsid proteins (full-length nucleocapsid and N-NTDs), the 277 278 respective expression constructs were used to transform E.coli BL21 (DE3) cells. Protein 279 expression was induced in 1 L TB medium at an optical density (OD₆₀₀) of 2.5 - 3 by addition 280 of 0.2 mM isopropyl-β-D-thiogalactopyranoside (IPTG) for 16 h at 20 °C. Cells were harvested by centrifugation (10 min at 6,000 x g) and the pellets were suspended in binding buffer 281 (1x PBS, ad 0.5 M NaCl, 50 mM imidazole, 2 mM phenylmethylsulfonyl fluoride, 2 mM MgCl₂, 282 150 µg/mL lysozyme (Merck) and 625 µg/mL DNasel (Applichem)). Cell suspensions were 283 sonified for 15 min (Bandelin Sonopuls HD70 - power MS72/D, cycle 50%) on ice, incubated 284 for 1 h at 4 °C in a rotary shaker followed by a second sonification step for 15 min. After 285 286 centrifugation (30 min at 20,000 x g), urea was added to a final concentration of 6 M to the 287 soluble protein extract. The extract was filtered through a 0.45 µm filter and loaded on a preequilibrated 1-mL HisTrap^{FF} column (GE Healthcare). The bound His-tagged nucleocapsid 288 proteins were eluted by a linear gradient (30 mL) ranging from 50 to 500 mM imidazole in 289 290 elution buffer (1x PBS, pH 7.4, 0.5 M NaCl, 6 M urea). Elution fractions (0.5 mL) containing the 291 His-tagged nucleocapsid proteins were pooled and dialyzed (D-Tube Dialyzer Mega, Novagen) 292 against PBS.

The viral S1-domains, SARS-CoV-2 RBD, and the stabilized trimeric SARS-CoV-2 Spike protein were expressed in Expi293 cells following the protocol as described in Stadlbauer *et al.*⁸.

All purified proteins were analyzed via standard SDS-PAGE followed by staining with InstantBlue Coomassie stain (Expedeon) and immunoblotting using an anti-His antibody (Penta-His Antibody, #34660, Qiagen) in combination with a donkey-anti-mouse antibody labeled with AlexaFluor647 (Invitrogen) on a Typhoon Trio (GE-Healthcare, Freiburg,

Germany; excitation 633 nm, emission filter settings 670 nm BP 30) to confirm protein integrity.
To further confirm correct expression, integrity, and purity, proteins were analysed by mass
spectrometry. To control the production reproducibility of the antigens, potential aggregation
and melting temperatures of the proteins were investigated by nano differential scanning
fluorimetry (nanoDSF) using a Prometheus (Nanotemper, Munich, Germany).

305

306 Commercial antigens

307 Two commercial antigens were used to complement the in-house-produced antigen panel.

The S2 ectodomain of the SARS-CoV-2 spike protein (aa 686 – 1213) was purchased from Sino Biological, Eschborn, Germany (cat # 40590, lot # LC14MC3007). A full-length nucleocapsid protein of SARS-CoV-2 was purchased from Aalto Bioreagents, Dublin, Ireland (cat # 6404-b, lot # 4629).

312

313 Bead-based serological multiplex assay

All antigens were covalently immobilized on spectrally distinct populations of carboxylated paramagnetic beads (MagPlex Microspheres, Luminex Corporation, Austin, TX) using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC)/ sulfo-N-hydroxysuccinimide (sNHS) chemistry. For immobilization, a magnetic particle processor (KingFisher 96, Thermo Scientific, Schwerte, Germany) was used.

319 Bead stocks were vortexed thoroughly and sonicated for 15 seconds. Subsequently, 83 µL of 320 0.065% (v/v) Triton X-100 and 1 mL of bead stock containing 12.5×10^7 beads of one single bead population were pipetted into each well. The beads were then washed twice with 500 µL 321 322 of activation buffer (100 mM Na₂HPO₄, pH 6.2, 0.005% (v/v) Triton X-100) and beads were 323 activated for 20 min in 300 µL of activation mix containing 5 mg/mL EDC and 5 mg/mL sNHS in activation buffer. Following activation, the beads were washed twice with 500 µL of coupling 324 buffer (500 mM MES, pH 5.0, 0.005% (v/v) Triton X-100) and the antigens were added to the 325 activated beads and incubated for 2 h at 21 °C to immobilize the antigens on the surface. 326

Antigen-coupled beads were washed twice with 800 μ L of wash buffer (1x PBS, 0.005 % (v/v) Triton X-100) and were finally resuspended in 1,000 μ L of storage buffer (1x PBS, 1 % (w/v) BSA, 0.05% (v/v) ProClin). The beads were stored at 4°C until further use.

330 To detect human IgG and IgA responses against SARS-CoV-2 and the endemic human coronaviruses (hCoV-NL63, hCoV-229E, hCoV-OC43 and hCoV-HKU1), the purified trimeric 331 Spike protein (S), S1-domain, S2-domain (Sino Biological GmbH, Europe), RBD, nucleocapsid 332 (N) and the N-terminal domain of nucleocapsid (N-NTD) of SARS-CoV-2 as well as the S1-333 334 domain, N, and N-NTD of the endemic hCoVs were immobilized on different bead populations as described above. The individual bead populations were combined into a bead mix. A bead-335 based multiplex assay was performed. Briefly, samples were incubated at a 1:400 dilution for 336 2 hours at 21 °C. Unbound antibodies were removed and the beads were washed three times 337 with 100 µL of wash buffer (1x PBS, 0.05% (v/v) Tween20) per well using a microplate washer 338 (Biotek 405TS, Biotek Instruments GmbH). Bound antibodies were detected with R-339 phycoerythrin labeled goat-anti-human IgG or IgA antibodies (incubation for 45 min at 21°C). 340 341 Measurements were performed using a Luminex FLEXMAP 3D instrument and the Luminex 342 xPONENT Software 4.3 (settings: sample size: 80 µL, 50 events, Gate: 7,500 – 15,000, 343 Reporter Gain: Standard PMT).

344

345 Data analysis

Data analysis and visualization was performed with R Studio (Version 1.2.5001, using R version 3.6.1) using the Median Fluorescent Intensity (MFI). Statistical analysis was performed using R package "stats" from the base repository. Mann-Whitney U test was used to determine difference between signal distributions from different sample groups. Spearman's ρ coefficient was calculated in order to correlate antigens by response from the entire sample set, followed by hierarchical clustering to group antigens. Fishers' exact test was used to calculate significance of overlap between sample groups.

353

355 **Quality control**

In order to test the repeatability of the MultiCoV-Ab assay three quality control samples (QCs) 356 357 were processed in duplicate on each test plate (n = 17) during the sample screening and inter-358 assay variance was assessed for each antigen in the multiplex. For intra-assay variance, 24 replicates for each of the three QC samples were analyzed on one plate. Achieved results are 359 presented in Extended Data Table 1 and Extended Data Fig. 2. A limit of detection (LOD) 360 for each antigen was determined by processing a blank in 24 replicates and LOD was set as 361 362 mean MFI + 3 standard deviations. Sample parallelism and comparability of paired serum and plasma samples was assessed over eight dilution steps ranging from 1:100 to 1:12,800 363 (Extended Data Fig. 2). A set of samples derived from 205 SARS-CoV-2-infected and 72 364 uninfected individuals was tested repeatedly with two different kit batches. The samples 365 classification in both runs matched 100 %. 366

367

368 Samples

A total of 1176 sera and plasma samples were used for the MultiCoV-Ab assay development. Ethical approval was granted from the Ethics Committee of Hannover Medical School (#9122_BO_K2020). Only de-identified samples were used for the MultiCoV-Ab assay development. All samples were pre-existing. Cohort age was 5-88 years; age was not known for 161 samples.

374 310 samples were from COVID-19 patients or convalescents. Samples were classified as
375 SARS-CoV-2 infected, if a positive SARS-CoV-2 RT-PCR was reported and/ or if
hospitalization/ quarantine for COVID-19 was indicated as part of the samples metadata. ΔT
defined as time between PCR test or symptom onset and blood draw was 0-73 days (median=
38 d; n=258). ΔT was not provided for 52 samples. SARS-CoV-2 infected samples used in this
study were collected after ethical review (9001_BO_K, Hannover Medical School;
179/2020/BO2, University Hospital Tübingen; 85/20, Ärztekammer des Saarlandes).

866 control samples were from non-SARS-CoV-2 infected individuals and were classified as
 non-infected as they were obtained prior to the emergence of SARS-CoV-2 in December 2019

or because they were taken from individuals who had not reported cold symptoms since thebeginning of 2020.

The majority of non-SARS-COV-2 infected samples was randomly selected and consistent of prepandemic blood donors, commercially available (Central BioHub GmbH, Berlin, Germany and BBI Solutions, Crumlin, UK) or bio-banked specimens. 365 samples were from the Memory and Morbidity in Augsburg Elderly (MEMO) study (a subcohort of the MONICA S2 cohort (WHO 1988)) and were included based on available serological titers for HSV-1, HSV-2, HHV-6 and EBV²⁴. 88 samples were obtained from transplanted patients with chronic respiratory conditions.

392 Collection of non-SARS-CoV-2 infected control samples had been approved by several ethic

votes: 3232-2016 (Ethics Committee of Hannover Medical School); 62/20 (Ethics Committees

394 of the Medical Faculty of the Saarland University at the Saarland Ärztekammer); WUM

- 17.02.1997 (Joint ethics committee of the University of Muenster and the Westphalian
- 396 Chamber of Physicians),

Additional sample details can be found in Extended Data Table 2.

398

399 Data availability

400 Primary Data including raw MFI and sample annotation will be made available upon request.

- 401
- 402 Code availability
- 403 R Code for data analysis will be made available upon request.

References 404

- Okba, N.M.A., et al. Severe Acute Respiratory Syndrome Coronavirus 2-Specific 405 1.
- 406 Antibody Responses in Coronavirus Disease Patients. Emerg Infect Dis 26, 1478-1488

407 (2020).

- Amanat, F., et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. 408 2. Nat Med (2020). 409
- Tan, W., et al. Viral Kinetics and Antibody Responses in Patients with COVID-19. 410 3.
- 411 medRxiv, 2020.2003.2024.20042382 (2020).
- Long, Q.X., et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat 412 4.

Med 26, 845-848 (2020). 413

- 5. Amanat, F. & Krammer, F. SARS-CoV-2 Vaccines: Status Report. Immunity 52, 583-589 414 415 (2020).
- Robbiani, D.F., et al. Convergent antibody responses to SARS-CoV-2 in convalescent 416 6. individuals. Nature (2020). 417
- 418 7. Lassaunière, R., et al. Evaluation of nine commercial SARS-CoV-2 immunoassays. 419 (medRxiv, 2020).
- Stadlbauer, D., et al. SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a
- Serological Assay, Antigen Production, and Test Setup. Curr Protoc Microbiol 57, e100 421
- 422 (2020).

8.

- 423 9. https://diagnostics.roche.com/global/en/products/params/elecsys-anti-sars-cov-2.html.
- 424 10. https://www.siemens-healthineers.com/de/laboratory-diagnostics/assays-by-diseases-
- conditions/infectious-disease-assays/cov2t-assay. 425
- 11. https://www.coronavirus-diagnostik.de/antikoerpertestsysteme-fuer-covid-19.html. 426
- 427 12. Burbelo, P.D., et al. Detection of Nucleocapsid Antibody to SARS-CoV-2 is More
- Sensitive than Antibody to Spike Protein in COVID-19 Patients, medRxiv (2020). 428
- 13. Ng, K., et al. Pre-existing and de novo humoral immunity to SARS-CoV-2 in humans. 429
- bioRxiv, 2020.2005.2014.095414 (2020). 430

- 431 14. Sun, B., et al. Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19
- 432 patients. Emerg Microbes Infect 9, 940-948 (2020).
- 433 15. den Hartog, G., et al. SARS-CoV-2-specific antibody detection for sero-epidemiology: a
- 434 multiplex analysis approach accounting for accurate seroprevalence. medRxiv,
- 435 2020.2006.2018.20133660 (2020).
- 436 16. Wang, H., et al. SARS-CoV-2 proteome microarray for mapping COVID-19 antibody
- 437 interactions at amino acid resolution. bioRxiv, 2020.2003.2026.994756 (2020).
- 438 17. Nelde, A., et al. SARS-CoV-2 T-cell epitopes define heterologous and COVID-19-
- 439 induced T-cell recognition. (2020).
- 18. Liu, L., et al. Anti-spike IgG causes severe acute lung injury by skewing macrophage
- 441 responses during acute SARS-CoV infection. JCI Insight 4(2019).
- 442 19. https://science.apa.at/rubrik/medizin_und_biotech/lschgl-
- 443 Studie_42_4_Prozent_sind_Antikoerper-
- 444 positiv/SCI_20200625_SCI39451352255218286.
- 20. Okba, N.M.A., et al. Particulate multivalent presentation of the receptor binding domain
- 446 induces protective immune responses against MERS-CoV. Emerg Microbes Infect 9,
- 447 1080-1091 (2020).
- 448 21. Yasui, F., et al. Prior immunization with severe acute respiratory syndrome (SARS)-
- 449 associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in
- 450 mice infected with SARS-CoV. J Immunol 181, 6337-6348 (2008).
- 451 22. Bolles, M., et al. A double-inactivated severe acute respiratory syndrome coronavirus
- 452 vaccine provides incomplete protection in mice and induces increased eosinophilic
- 453 proinflammatory pulmonary response upon challenge. J Virol 85, 12201-12215 (2011).
- 454 23. Kang, S., et al. Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding
- domain reveals potential unique drug targeting sites. Acta Pharm Sin B (2020).
- 456 24. Zeeb, M., et al. Seropositivity for pathogens associated with chronic infections is a risk
- 457 factor for all-cause mortality in the elderly: findings from the Memory and Morbidity in
- 458 Augsburg Elderly (MEMO) Study. GeroScience (2020).

459 Acknowledgements

This work has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 101003480 – CORESMA as well as from the German Federal Ministry for Research and Education/the Helmholtz Association. We thank Florian Krammer providing us with expression plasmids for the Spike Trimer and RBD. We thank Shannon Layland for critical proofreading of the manuscript.

465

466 Author Contributions

M.B. designed and performed experiments and data analysis; M.S. designed experiments; 467 D.J., J.H., S.F., F.R., planned and performed experiments; A.Z. performed mass spectrometry 468 analysis; J.H. performed nanoDSF analyses; H.D., B.T., P.K., F.W., U.R. designed, cloned, 469 expressed and purified the antigens; S.H. and A.P. performed sample analysis; T.B., A.B., 470 S.L., S.S., M.C., T.I., H-G.R., A.N., J.W., M.T., T.O.J. arranged sample and data collection; 471 M.T., T.O.J, G.K. supported the study planning; N.S-M. planned the assay development and 472 473 validation and designed experiments; M.B., M.S., U.R. and N.S-M. wrote the manuscript. All 474 authors reviewed the manuscript.

475

476 Competing interests

T.O.J is a scientific advisor for Luminex. N.S-M. was a speaker at Luminex user meetings in
the past. The Natural and Medical Sciences Institute at the University of Tuebingen is involved
in applied research projects as a fee for services with Luminex.

480 Figure Legends

481

482 Fig. 1. | MultiCoV-Ab assay, a sensitive and specific tool to monitor SARS-CoV-2 antibody responses. a, Control sera (blue, n = 72) and sera from individuals with PCR-483 confirmed SARS-CoV-2 infection (red, n = 205) were screened in a multiplex bead-based 484 assay using Luminex technology (MultiCoV-Ab) to quantify IgG or IgA responses to various 485 486 antigens. Reactivity towards trimeric SARS-CoV-2 spike protein (Spike Trimer) or SARS-CoV-487 2 receptor binding domain of spike (RBD) was found to be the best predictor of SARS-CoV-2 infection. Data are presented as Box-Whisker plots of sample median fluorescence intensity 488 (MFI) on a logarithmic scale. Outliers determined by 1.5 times IQR of log-transformed data are 489 depicted as circles. b, Sample set from a, was used to compare assay performance of the 490 MultiCoV-Ab assay using combined Spike Trimer and RBD antigens with commercially 491 available single analyte SARS-CoV-2 assays which detect total Ig (Elecsys Anti-SARS-CoV-2 492 (Roche); ADVIA Centaur SARS-CoV-2 Total (COV2T) (Siemens Healthineers)) or IgG (Anti-493 494 SARS-CoV-2-ELISA - IgG (Euroimmun)) or IgA (Anti-SARS-CoV-2-ELISA - IgA (Euroimmun)). SARS-CoV-2 infection status of samples is indicated as SARS-CoV-2 positive (PCR) or 495 negative. Antibody test results were classified as negative (blue), positive (red) or borderline 496 497 (grey) as per the manufacturer's definition. Only samples with divergent antibody test results 498 are shown.

499 Fig. 2. | Combination of 2 Spike protein variants and isotype profiling by multiplex assay

500 increases accuracy to identify SARS-CoV-2 antibody positive individuals.

501 a. An extended sample set of SARS-CoV-2-uninfected (n = 866) and SARS-CoV-2-infected individuals (n = 310) was used to further validate our MultiCoV-Ab assay. Age, gender, SARS-502 CoV-2 infection status and hospitalization status of study population are shown. NA: 503 information was not provided. b, MultiCoV-Ab assay sensitivity and specificity were calculated 504 505 for IgA or IgG based on a single analyte or a combined cut-off of Spike Trimer and RBD (IgG 506 or IgA overall). A cut-off combining IgG and IgA was calculated as well. c-d, Scatterplot detailing MultiCoV-Ab assay cut-offs. Signal to cut-off (S/CO) values are displayed for Spike 507 508 Trimer against RBD on a logarithmic scale. For $IgG(c_1)$, cut-offs are visualized by straight lines and SARS-CoV-2-infected and uninfected samples are separated by color (black circles -509 SARS-CoV-2-uninfected; red circles - SARS-CoV-2-infected). For IgA (d,) cut-offs are 510 visualized as dashed lines and S/CO of 2 used for the combined cut-off is shown as straight 511 lines. SARS-CoV-2-infected samples are split into IgG-positives and -negatives by color as 512 513 indicated in the plot. e-f, Scatterplots display IgG response to additional SARS-CoV-2 antigens contained in the MultiCoV-Ab panel: MFI for Spike subdomains S1 vs S2 (e,) or Nucleocapsid 514 antigens N vs N-NTD (f,) are displayed on logarithmic scale. SARS-CoV-2-uninfected samples 515 516 are distinguished from SARS-CoV-2-infected and MultiCoV-Ab classification into positives or 517 negatives as indicated by color.

518 Fig. 3. | Multiplex-based seroprofiling allows in-depth characterization of SARS-CoV-2

519 antibody responses

520 a, Kinetic of SARS-CoV-2 antigen-specific IgA and IgG responses is shown for indicated days after symptom onset for six SARS-CoV-2-specific antigens for five different patients. b-c, 521 Samples of SARS-CoV-2-infected individuals were analysed to identify antigen- and isotype-522 specific antibody responses based on hospitalization indicating disease severity (b,) or age 523 524 (c,). Data is presented as Box-Whisker plots of sample MFI on a logarithmic scale. Outliers determined by 1.5 times IQR of log-transformed data are depicted as circles. p-value (Mann-525 Whitney U test, two-sided) is displayed at the top of the boxes, indicating differences between 526 527 signal distribution for respective groups.

528 Fig. 4. | Correlation of endemic and SARS CoV-2 antibody responses

a, Correlation of IgG response for the entire sample set (n = 1176) is visualized as heatmap 529 530 based on Spearman's p coefficient; dendrogram on the right side displays antigens after hierarchical clustering was performed. b-c, Immune responses (IgG and IgA) towards hCoV 531 S1 (b,) and N (c,) proteins are presented as Box-Whisker plots of sample MFI on a logarithmic 532 scale for SARS-CoV-2-infected (red, n = 310) and uninfected (blue, n = 866) individuals. 533 534 Outliers determined by 1.5 times IQR of log-transformed data are depicted as circles. d-e, 535 Relative levels of IgG-specific immune response towards hCoV S1 (d,) and N (e,) proteins are presented as Box-Whisker plots / stripchart overlays of log-transformed and per-antigen 536 scaled and centred MFI for the sample subsets of Spike Trimer false positives (blue, n =17) 537 and combined IgG + IgA false negatives (red, n = 31). **f**, From the entire study population, 538 groups of α - or β -hCoV high and low responders were built as indicated. High responder were 539 defined as samples with above average MFI values for S1 and N-specific IgGs of the 540 541 respective hCoV clade. Low responders were defined with below MFI values, correspondingly. 542 Responder groups (i) α -hCoV \uparrow , red, n = 233, (ii) β -hCoV \uparrow , green, n = 254, (iii) α -hCoV \downarrow , blue, n = 172 (iv) β -hCoV \downarrow , purple, n = 210 are shown as Box-Whisker plots of log-transformed and 543 544 per-antigen scaled and centred MFI values across hCoV N and S1 antigens. Outliers 545 determined by 1.5 times IQR are depicted as circles. The over- or under-representation of 546 SARS-CoV-2 responders (SARS-CoV-2 +, n = 279, as determined by positive MultiCoV-Ab 547 classification) within the four sample groups is visualized in Venn diagrams, stochastic 548 significance was calculated using Fisher's exact test (two-sided).

549

550 Extended Data Figure Legends

551 Extended Data Fig.1

SDS-PAGE analysis of the recombinant viral antigens used in this study. To test for purity and integrity 1 - 2 μg of indicated recombinant proteins were boiled in reducing SDS-sample buffer and subjected to a gradient (4 - 20%) SDS-PAGE followed by coomassie staining. SARS-CoV-2_Spike, SARS-CoV-2_RBD and the S1-domains of SARS-CoV-2, hCoV-NL63, hCoV-229E, hCoV-OC43 and hCoV-HKU1 were produced in ExpiHEK[™] cells. Nucleocapsid (N) and Nterminal domain of nucleocapsid (N-NTD) of SARS-CoV-2, hCoV-NL63, hCoV-229E, hCoV-OC43 and hCoV-HKU1 were produced in *E.coli*.

559

560 Extended Data Fig.2

a, Three quality control (QC) samples, as well as a sample of assay buffer (blank sample) were 561 562 processed in duplicates on every plate. Performance across 17 assay runs is depicted and mean and %CVs are shown on the left side. For plate 14, a processing error lead to exclusion 563 of one blank sample from this evaluation. **b**, To assess parallelism of signals from different 564 samples, 6 unique serum samples were processed over a dilution series of 8 steps from 1:100 565 to 1:12,800. For 3 samples, paired plasma (EDTA and/or Heparin) were available and 566 processed together. For IgG and IgA detection of Spike Trimer and RBD, MFI are plotted 567 against sample dilution. Color indicates unique sample and shapes indicate sample type. 568

569

570 Extended Data Fig.3

a-d, Scatterplots of sample set with defined SARS-CoV-2 infection status (infected: red, n=205;
uninfected: black, n=72) to compare performance of the MultiCoV-Ab Spike Trimer vs indicated
antigens of commercial SARS–CoV-2 test kits. Signals are depicted as Signal to cut-off ratios
(S/CO) on a logarithmic scale. Lines indicate the respective cut-off values as defined by the
manufacturer to determine positive and negative test results.

576

578 Extended Data Fig.4

a, Correlation of IgA response for the entire sample set (n=1176) is visualized as heatmap 579 580 based on Spearman's p coefficient; dendrogram on the right side displays antigens after 581 hierarchical clustering was performed. b, Immune response (IgG and IgA) towards hCoV N-NTD proteins are presented as Box-Whisker plots of sample MFI on a logarithmic scale for 582 SARS-CoV-2-infected (red, n=310) and uninfected (blue, n=866) individuals. Outliers 583 584 determined by 1.5 times IQR of log-transformed data are depicted as circles. c, Relative levels 585 of IgG-specific immune response towards hCoV N-NTD proteins are presented as Box-Whisker plots / stripchart overlays of log-transformed and per-antigen scaled and centred MFI 586 for the sample subsets of Spike Trimer false positives (blue, n=17) and combined IgG + IgA 587 false negatives (red, n=31). 588

589

590 Extended Data Table 1

Intra- and inter-assay variance were determined by repeated measurement of QC samples
and blank sample as replicates on one plate and in duplicates over 17 plates, respectively.
Standard deviation relative to mean (%CV) is given for each antigen. A limit of detection (LOD)
was calculated from 24 blank sample replicates on the same plate as the mean MFI + 3 times
standard deviation.

596

597 Extended Data Table 2

Complete overview of study sample set. Samples are divided into columns by age groups and 598 599 gender. NA: Information was not available. Samples from SARS-CoV-2-infected donors are further split up by hospitalization status. Age and gender of patients from which multiple 600 601 samples were available for time course analyses are indicated. SARS-CoV-2-uninfected 602 samples are further divided into samples drawn during the pandemic, which was defined as all 603 samples taken on 01.01.2020 or later, and pre-pandemic samples. 147 samples with previous 604 hCoV infection were included in the SARS-CoV-2-uninfected group. Detailed diagnosis of 605 hCoV subspecies is indicated where available. Other sample conditions for special groups of 606 uninfected samples are listed.



Figure 2

а										
Age group	≤3	9	40-	59	≥6	≥60				Σ
n	29	9	24	1	47	75		161		1,176
Gender	М	F	М	F	М	F	М	F	NA	
n	139	160	144	97	271	204	5	3	153	1,176
SARS-CoV-2 infected	60	51	71	63	42	17	3	3	0	310
hospitalised	6	2	14	6	23	4	0	0	0	55
non-hospitalised	52	43	49	43	13	8	0	0	0	208
hospitalisation NA	2	6	8	14	6	5	3	3	0	47
SARS-CoV-2 uninfected	79	109	73	34	229	187	0	0	153	866

	Correctl	y classified	Sensitivity	Specificit	
	infected	uninfected	(%)	(%)	
IgG Spike Trimer	277	849	89.35	98.04	
IgG RBD	276	862	89.03	99.54	
IgG overall	275	866	88.71	100.00	
IgA Spike Trimer	272	850	87.74	98.15	
IgA RBD	255	855	82.26	98.73	
IgA overall	254	864	81.94	99.77	
Combined IgG + IgA	279	866	90.00	100.00	

b

d





Combined IgG + IgA cut-off





Figure 3







Extended Data - Table 1

				SARS-CoV-2			hCoV NL63			hCoV 229E			hCoV OC43			hCoV HKU1				
			Spike																	
			Trimer	RBD	S1	S2	N	N-NTD	S1	N	N-NTD	S1	Ν	N-NTD	S1	N	N-NTD	S1	Ν	N-NTD
Inter-assay IgC variance (%CV) n = 34, duplicates, 17 plates IgA		QC1	3.7	3.3	3.4	3.7	2.8	7.4	3.5	3.2	4.4	3.3	2.8	5.2	3.1	6.0	4.4	3.4	4.7	5.4
	100	QC2	4.1	4.6	6.9	3.4	5.3	4.8	3.0	2.2	6.3	2.4	2.1	6.7	2.7	4.5	2.3	2.7	5.1	2.8
	Igo	QC3	3.4	2.4	2.3	3.6	2.1	4.6	3.1	2.5	3.5	2.9	2.0	4.7	2.9	6.4	4.6	3.2	3.2	3.5
		Blank	5.4	5.6	6.7	6.4	5.6	6.1	6.3	7.1	5.7	9.1	6.1	6.1	5.6	7.3	4.1	4.9	6.1	8.3
		QC1	3.9	4.6	4.9	4.0	5.1	5.0	4.2	3.6	3.9	4.0	5.3	7.4	4.3	7.4	5.0	4.2	6.0	5.0
	1=0	QC2	4.6	5.0	5.1	3.9	3.9	4.2	3.7	2.4	7.6	2.9	2.2	6.0	4.1	16.4	4.2	4.3	5.5	3.9
	IgA	QC3	3.9	3.8	4.5	3.4	3.4	4.8	3.9	2.8	4.0	3.0	5.1	4.5	3.6	6.1	4.1	3.7	4.5	5.1
		Blank	6.7	5.3	8.2	6.3	5.3	5.3	3.3	5.0	5.0 6.7	7.0	6.1	5.3	7.1	4.7	6.0	6.8	6.3	
		QC1	2.5	1.9	2.0	2.1	1.8	2.1	2.4	1.7	2.8	2.0	2.7	3.2	1.9	2.0	2.2	2.7	2.4	2.2
	1-0	QC2	5.9	4.3	4.1	2.8	2.7	3.2	1.9	1.9	2.6	2.0	2.2	2.7	2.2	1.6	2.1	2.5	3.1	2.5
	igo	QC3	1.6	4.3	5.1	1.9	1.9	4.5	4.2	1.7	3.2	3.3	4.1	5.7	3.2	3.1	5.5	5.6	6.0	8.4
Intra-assay		Blank	6.0	5.6	5.2	5.8	5.2	4.2	5.0	4.8	4.8	7.3	6.2	6.3	6.5	6.2	4.4	6.1	6.0	6.2
variance (%CV)		QC1	2.5	3.3	5.2	3.8	3.7	4.2	3.2	2.3	2.2	2.0	4.8	4.7	2.9	4.7	3.4	3.3	4.5	4.3
n = 24	IgA	QC2	4.8	5.7	5.7	3.2	4.1	4.3	3.4	2.0	5.7	2.1	2.1	6.1	3.0	3.1	1.9	3.9	6.4	3.8
		QC3	3.1	4.7	5.5	3.0	4.1	4.4	3.7	2.7	3.7	2.7	5.4	5.8	2.6	4.1	3.1	2.4	4.5	4.3
		Blank	5.8	5.3	6.3	5.0	5.4	5.5	4.5	5.6	5.3	7.2	6.3	7.0	6.7	9.5	7.3	5.2	8.8	7.0
LOD* (MFI)	lgG		32	26	23	29	38	33	29	28	26	65	35	24	33	30	33	37	33	25
n = 24	IgA		31	26	26	27	37	32	57	28	40	28	36	22	35	28	32	33	39	28

*Blank mean MFI + 3 * sd

Age	5	39	40	-59	≥(60		Σ		
n	2	99	24	41	47	75		1,176		
Gender	M F		М	F	М	F	М	F	NA*	
n	139	160	144	97	271	204	5	3	153	1,176
SARS-CoV-2-infected (total)	60	51	71	63	42	17	3	3	0	310
Hospitalized (for COVID19)	6	2	14	6	23	4	0	0	0	55
Non-Hospitalized	52	43	49	43	13	8	0	0	0	208
Hospitalisation NA	2 6		8	14	6	5	3	3	0	47
Patients with time series	2	0	0	0	2	1	0	0	0	5
SARS-CoV-2-uninfected (total)	79	109	73	34	229	187	2	0	153	866
Sample during pandemic	10	10	12	14	7	5	1	0	6	65
Sample pre-pandemic	69	99	61	20	222	182	1	0	147	801
Previous hCoV Infection	19	18	45	20	29	16	0	0	0	147
confirmed NL63	2	0	3	1	2	2	0	0	0	10
confirmed 229	5	1	4	1	5	4	0	0	0	20
confirmed OC43	0	1	14	1	6	5	0	0	0	27
confirmed HKU1	3	1	4	2	5	0	0	0	0	15
unknown hCoV	9	15	20	15	11	5	0	0	0	75
Pregnant	0	9	0	1	0	0	0	0	0	10
RF/HAMA samples	0	0	0	0	0	0	0	0	6	6
PCT > 3 ng/mL	0	0	0	0	0	0	0	0	21	21
Neuroinflammatory disease	6	6	1	0	1	1	0	0	0	15

Extended Data - Table 2

Extended Data - Figure 1







Extended Data Figure 4





